JP2004521908A - Ｍｍｐ阻害剤としてのトリアゾロ化合物 - Google Patents

Ｍｍｐ阻害剤としてのトリアゾロ化合物 Download PDF

Info

Publication number
JP2004521908A
JP2004521908A JP2002564526A JP2002564526A JP2004521908A JP 2004521908 A JP2004521908 A JP 2004521908A JP 2002564526 A JP2002564526 A JP 2002564526A JP 2002564526 A JP2002564526 A JP 2002564526A JP 2004521908 A JP2004521908 A JP 2004521908A
Authority
JP
Japan
Prior art keywords
alkyl
formula
compound
group
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2002564526A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004521908A5 (https=
Inventor
シャルル・アンドリアンジャーラ
アンリ・ジャコベル
ベルナール・ゴウディリエール
フランシーン・ブレザール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of JP2004521908A publication Critical patent/JP2004521908A/ja
Publication of JP2004521908A5 publication Critical patent/JP2004521908A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2002564526A 2001-02-14 2002-02-11 Ｍｍｐ阻害剤としてのトリアゾロ化合物 Abandoned JP2004521908A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26875701P 2001-02-14 2001-02-14
PCT/EP2002/001961 WO2002064595A1 (en) 2001-02-14 2002-02-11 Triazolo compounds as mmp inhibitors

Publications (2)

Publication Number Publication Date
JP2004521908A true JP2004521908A (ja) 2004-07-22
JP2004521908A5 JP2004521908A5 (https=) 2005-08-04

Family

ID=23024335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002564526A Abandoned JP2004521908A (ja) 2001-02-14 2002-02-11 Ｍｍｐ阻害剤としてのトリアゾロ化合物

Country Status (15)

Country Link
US (1) US6849637B2 (https=)
EP (1) EP1362048B1 (https=)
JP (1) JP2004521908A (https=)
AR (1) AR032677A1 (https=)
AT (1) ATE294805T1 (https=)
BR (1) BR0207270A (https=)
CA (1) CA2437588A1 (https=)
DE (1) DE60203995T2 (https=)
ES (1) ES2239216T3 (https=)
HN (1) HN2002000038A (https=)
MX (1) MXPA03007249A (https=)
PA (1) PA8539501A1 (https=)
PE (1) PE20020885A1 (https=)
SV (1) SV2002000875A (https=)
WO (1) WO2002064595A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540687A (ja) * 2005-05-20 2008-11-20 アラントス−フアーマシユーテイカルズ・インコーポレイテツド ピリミジン若しくはトリアジン縮合二環式メタロプロテアーゼ阻害薬

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
EP1370562A1 (en) * 2001-02-14 2003-12-17 Warner-Lambert Company LLC Thieno[2,3-d]pyrimidindione derivatives as matrix metalloproteinase inhibitors
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
EP1434585A1 (en) 2001-10-12 2004-07-07 Warner-Lambert Company LLC Alkyne matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
BR0312708A (pt) * 2002-07-17 2005-04-26 Warner Lambert Co Combinação de um inibidor alcina alostérico de metaloproteinase-13 de matriz com celecoxib ou valdecoxib
BR0312943A (pt) * 2002-07-17 2005-07-12 Warner Lambert Co Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib
WO2004006913A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
AU2003281169A1 (en) * 2002-07-17 2004-02-02 Warner-Lambert Company Llc Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
WO2004014375A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
BR0313724A (pt) 2002-08-13 2005-06-28 Warner Lambert Co Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz
WO2004014923A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
AU2003249477A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
AU2003249539A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
AU2003249535A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
MXPA05001603A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados monociclicos como inhibidores de metaloproteinasa de matriz.
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004014378A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
ES2283851T3 (es) 2002-08-13 2007-11-01 Warner-Lambert Company Llc Derivados de pirimidin-2,4-diona como inhibidores de las metaloproteinasas de matriz.
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
WO2004014869A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
CA2497658A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
WO2004014867A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Matrix metalloproteinase inhibitors and methods for identification of lead compounds
AU2003250482A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
BR0313727A (pt) * 2002-08-13 2005-07-12 Warner Lambert Co Derivados de isoquinolina como inibidores de metaloproteinase da matriz
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US7795877B2 (en) * 2006-11-02 2010-09-14 Current Technologies, Llc Power line communication and power distribution parameter measurement system and method
CA2670083A1 (en) * 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
MX2010007419A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DE102010031945A1 (de) * 2010-07-22 2012-01-26 Osram Opto Semiconductors Gmbh Halbleiterbauelement und Verfahren zur Herstellung eines Halbleiterbauelements
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
CN115197225B (zh) * 2021-09-03 2023-04-11 贵州大学 一种五元杂环并喹唑啉酮类化合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455311A (en) * 1981-08-28 1984-06-19 Hoffmann-La Roche Inc. Imidazoquinazoline derivatives which inhibit the aggregation of blood platelets, inhibit gastric secretion or have activity on the circulatory system
IL66835A (en) * 1981-09-24 1988-05-31 Roussel Uclaf 1,4-disubstituted(1,2,4)triazolo(4,3-alpha)quinazolin-5(4h)-one derivatives and their salts,their preparation and pharmaceutical compositions containing them
DE3677445D1 (de) * 1985-09-30 1991-03-14 Ciba Geigy Ag 2-substituierte-e-kondensierte(1,5-c)-pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
US6008243A (en) 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
KR20000057444A (ko) 1996-12-09 2000-09-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 심기능부전 및 심실확장의 치료 및 예방 방법
JPH11199512A (ja) 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用
UA59453C2 (uk) 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
FR2792938B1 (fr) * 1999-04-28 2001-07-06 Warner Lambert Co NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
PA8498701A1 (es) 1999-08-12 2002-08-26 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
US6934639B1 (en) 2000-02-25 2005-08-23 Wyeth Methods for designing agents that interact with MMP-13
EP1138680A1 (en) 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
BR0114913A (pt) 2000-10-26 2003-07-01 Pfizer Prod Inc Inibidores de metaloproteinase de espiro-pirimidina-2,4,6-triona
IL154946A0 (en) 2000-10-26 2003-10-31 Pfizer Prod Inc Pyrimidine-2,4,6-trione metalloproteinase inhibitors
PA8539401A1 (es) 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
PA8539301A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
WO2003033478A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors
EP1434585A1 (en) 2001-10-12 2004-07-07 Warner-Lambert Company LLC Alkyne matrix metalloproteinase inhibitors
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
WO2003076416A1 (en) 2002-03-08 2003-09-18 Warner-Lambert Company Llc Oxo azabicyclic compounds
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
WO2004000321A1 (en) 2002-06-25 2003-12-31 Warner-Lambert Company Llc Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
AU2003249539A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540687A (ja) * 2005-05-20 2008-11-20 アラントス−フアーマシユーテイカルズ・インコーポレイテツド ピリミジン若しくはトリアジン縮合二環式メタロプロテアーゼ阻害薬
JP2013181033A (ja) * 2005-05-20 2013-09-12 Alantos Pharmaceuticals Holding Inc ヘテロ二環式メタロプロテアーゼ阻害薬

Also Published As

Publication number Publication date
PA8539501A1 (es) 2002-09-30
WO2002064595A1 (en) 2002-08-22
AR032677A1 (es) 2003-11-19
US20020151558A1 (en) 2002-10-17
ES2239216T3 (es) 2005-09-16
MXPA03007249A (es) 2005-02-14
PE20020885A1 (es) 2002-10-26
BR0207270A (pt) 2004-02-10
CA2437588A1 (en) 2002-08-22
EP1362048B1 (en) 2005-05-04
ATE294805T1 (de) 2005-05-15
EP1362048A1 (en) 2003-11-19
DE60203995D1 (de) 2005-06-09
SV2002000875A (es) 2002-10-04
US6849637B2 (en) 2005-02-01
DE60203995T2 (de) 2005-09-22
HN2002000038A (es) 2002-09-05

Similar Documents

Publication Publication Date Title
EP1362048B1 (en) Triazolo compounds as mmp inhibitors
DE60001229T2 (de) Triarylimidazole
US20050004126A1 (en) Method of determining potential allosterically-binding matrix metalloproteinase inhibitors
US20020193377A1 (en) Quinazolines as MMP-13 inhibitors
JP2000513717A (ja) カルボリン誘導体
US20030130278A1 (en) Alkynylated fused ring pyrimidine compounds
JP2010508288A (ja) キナーゼ阻害剤として有用なヘテロサイクリックアミド化合物
KR20110067029A (ko) 안드로겐 수용체 조절제로서 신규의 이미다졸리딘 화합물
WO2003033478A1 (en) Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors
JP2006516653A (ja) キナーゼ阻害剤ピロロトリアジンの製造方法
JPWO1995018130A1 (ja) ３環性ベンゾアゼピンおよびベンゾチアゼピン誘導体
DE69403479T2 (de) TRICYCLISCHE INHIBITOREN VON GP II b III a REZEPTOREN
JPH0641095A (ja) 置換トリアゾロンおよびトリアゾールジオンの抗うつ性３−ハロフェニルピペラジニル−プロピル誘導体
US6093714A (en) Tricyclic benzazepine compounds
JPWO1997000258A1 (ja) 三環性ベンゾアゼピン化合物
SK284112B6 (sk) 5-Substituované 1,2,4-tiadiazolylové deriváty, spôsob ich výroby a farmaceutické kompozície
CN113754635A (zh) 稠环类化合物及其制备方法和用途
FI82456B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1-fenyl-1,2,4-tiadiazin-1-oxidderivat.
WO2003033477A1 (en) Alkynlated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitor
CN116554103A (zh) 苯基吡唑类化合物及其应用
EP4384268B1 (en) Small molecule urea derivatives as sting antagonists
WO1994003439A1 (en) Antiproliferative tricyclic compounds
JP2007099642A (ja) 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物
JPH0227345B2 (https=)
JP2002532500A (ja) １，４−ベンゾジアゼピノン誘導体並びにそれらのインテグリン拮抗薬としての使用

Legal Events

Date Code Title Description
A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20051228